LIGAND PHARMACEUTICALS INC (LGND)
LIGAND PHARMACEUTICALS INC (LGND) from its SEC filings: 2025 revenue $268.1 million (+60% vs the year before), net margin 46%, free cash flow $48.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $268.1 million |
| Revenue growth | +60% |
| Net income | $124.5 million |
| Net margin | 46.4% |
| Free cash flow | $48.9 million |
| Diluted EPS | $6.13 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +34% |
| Cash | $1.0 billion |
| Long-term debt | $1.1 billion |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.